The Cooper Companies, Inc.
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
What does it do?
Cooper Companies makes two things: contact lenses and medical tools for women's health. Their CooperVision arm makes lenses that correct common vision problems like astigmatism (blurry vision from an irregular eye shape) and presbyopia (the reading-glasses problem that hits people in their 40s). Their CooperSurgical arm sells fertility clinic equipment and contraceptive devices to hospitals and clinics. Think of them as the behind-the-scenes supplier for two very everyday human needs — seeing clearly and starting a family.
Contact lenses are a subscription business disguised as a healthcare product — people who wear them buy new ones every month or every day, forever, which means Cooper gets reliable, repeat revenue that doesn't dry up in a recession. The global myopia epidemic (more people need glasses and lenses than ever before, especially children in Asia) is a genuine long-term tailwind that makes this market bigger every year. Meanwhile, their fertility business puts them inside one of the fastest-growing areas of healthcare as more people delay having children and turn to IVF.
How does it make money?
Cooper generated $4.1 billion in revenue last year, up from $3.9 billion the prior year — that's about 5% growth. The vast majority comes from CooperVision, which sells daily, bi-weekly, and monthly contact lenses to eye doctors and opticians worldwide who then sell them to patients. CooperSurgical makes money selling fertility lab equipment, embryo storage devices, and contraceptives like intrauterine devices (IUDs) to hospitals and fertility clinics. Net income (what's left after all costs) came in at $0.4 billion, meaning they keep roughly 10 cents of profit for every dollar they bring in.
Why do investors care?
The growth story here is twofold: a structural rise in short-sightedness globally (the World Health Organization estimates half the world's population could be myopic by 2050) and the steady expansion of IVF and fertility treatments as a mainstream medical service. For the bull case to work, Cooper needs to keep winning market share in daily disposable lenses — the fastest-growing and most profitable part of the lens market — while its MiSight lens, which is clinically proven to slow myopia in children, scales into a major product. The fertility segment also needs to keep growing as IVF clinic volumes rise across the US and Europe.
Deep Dive
MemberA full investor briefing on The Cooper Companies, Inc. — history, leadership, risks, and outlook.